Value of surgery in recurrent platinum-resistance ovarian cancer.

doi:10.7504/fk2015020106

Abstract

Abstract:

Abstract:Secondary cytoreductive surgery (SCS) has been given more and more attention in the management of the recurrent platinum-resistance ovarian cancer.More and more studies have demonstrated that selected patients might have favorable outcomes and longer survival interval with optimal secondary cytoreductive surgery.The rationality，feasibility，indications as well as postoperative adjuvant therapy are discussed in the paper.

Key words: recurrent ovarian cancer, platinum-resistance ovarian cancer, secondary cytoreductive surgery

摘要：

二次肿瘤细胞减灭术在复发性耐药性卵巢癌治疗中的价值越来越受到关注。目前大量研究表明，满意的二次肿瘤细胞减灭术可以改善部分患者的预后、延长生存期。文章探讨了复发性耐药性卵巢癌手术治疗的合理性、可行性，适宜人群的选择以及术后辅助治疗等问题。

关键词: 复发性卵巢癌, 耐药性卵巢癌, 二次肿瘤细胞减灭术

CLC Number:

R737.3

YANG Zhuo，WANG Dan-bo.. Value of surgery in recurrent platinum-resistance ovarian cancer.[J]. Acta Metallurgica Sinica, DOI: 10.7504/fk2015020106.

杨卓，王丹波. 复发性耐药性卵巢癌手术价值[J]. 中国实用妇科与产科杂志, DOI: 10.7504/fk2015020106.

References

［1］   Ushijima K.Treatment for recurrent ovarian cancer-at first relapse［J］.J Oncol，2010，2010:497429-497436.

［2］    Wang F，Ye Y，Xu X，et al.CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery［J］.J Ovarian Res，2013，6(1):14-23.

［3］    Ebina Y，Watari H，Kaneuchi M，et al.Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer［J］.Eur J Nucl Med Mol Imaging，2014，41(3):446-451.

［4］    Bristow RE，Puri I，Chi DS.Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis ［J］.Gynecol Oncol，2009，112(1):265-274.

［5］    Woelber L，Jung S，Eulenburg C，et al.Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer［J］.Eur J Surg Oncol，2010，36(6):583-588.

［6］    Fleming ND，Cass I，Walsh CS，et al.CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer［J］.Gynecol Oncol，2011，121(2):249-252.

［7］    Zang RY，Li ZT，Tang J，et al.Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?［J］.Cancer，2004，100(6):1152-1161.

［8］    Zang RY，Zhang ZY，Li ZT，et al.Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer［J］.J Surg Oncol，2000，75(1):24-30.

［9］    Harter P，Hahmann M，Lueck HJ，et al.Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors，surgical implications，and prognostic value of peritoneal carcinomatosis［J］.Ann Surg Oncol，2009，16(5):1324-1330.

［10］    Harter P，Sehouli J，Reuss A，et al.Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP Ⅱ.A project of the AGO Kommission OVAR，AGO Study Group，NOGGO，AGO-Austria，and MITO［J］.Int J Gynecol Cancer，2011，21(2):289-295.

［11］    Tian WJ，Chi DS，Sehouli J，et al.A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection［J］.Ann Surg Oncol，2012，19(2):597-604.

［12］    Tan WJ，Wong JF，Chia CS，et al.Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: an Asian perspective［J］.Ann Surg Oncol，2013，20(13):4219-4223.

［13］    Deraco M，Virzi S，Iusco DR，et al.Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study［J］.BJOG，2012，119(7):800-809.

（2014-11-15收稿）

[1]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(8): 769-772.
[2]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 673-675.
[3]	TAO Xiang, CHEN Ting-ting, ZHOU Xian-rong. Research status of histopathology and molecular pathology of gestational trophoblastic disease. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 676-680.
[4]	PENG Mei-lian, LIN Kai-wu, WENG Zong-jie, WU Qi-bin, SUN Peng-ming. . Imaging features and significance of gestational trophoblastic disease. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 680-684.
[5]	CHENG Guang-yan, QU Peng-peng.. Standardized management of hydatidiform mole. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 684-687.
[6]	LIU Xiao-mei, LI Xiu-qin.. Treatment for low-risk gestational trophoblastic neoplasia. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 687-691.
[7]	LI Ke-min, YIN Ru-tie. Treatment for high-risk gestational trophoblastic neoplasia. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 691-693.
[8]	CHENG Hong-yan, XIANG Yang. . Immunotherapy for gestational trophoblastic neoplasia. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 693-696.
[9]	WANG Fen-fen, BAO Ke-chun, CHENG Xiao-dong. Treatment for special pathological types of gestational trophoblastic neoplasia. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 696-701.
[10]	XI Ling, SUN Yue.. Fertility preservation in gestational trophoblastic neoplasia. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 701-704.
[11]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 705-713.
[12]	CHENG Ao-shuang, LIN Zhong-qiu. Protection and preservation of the fertility of female malignant tumor patients. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(6): 604-609.
[13]	HUANG Chen-yang, SUN Hai-xiang. Selection of protocols about ovulation induction and embryo transfer for patients with gynecological malignant tumors. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(6): 614-618.
[14]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(6): 628-633.
[15]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(6): 634-641.